BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19841031)

  • 1. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
    Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
    J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
    Herbrecht R; Maertens J; Baila L; Aoun M; Heinz W; Martino R; Schwartz S; Ullmann AJ; Meert L; Paesmans M; Marchetti O; Akan H; Ameye L; Shivaprakash M; Viscoli C
    Bone Marrow Transplant; 2010 Jul; 45(7):1227-33. PubMed ID: 20062093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
    Maertens J; Egerer G; Shin WS; Reichert D; Stek M; Chandwani S; Shivaprakash M; Viscoli C;
    BMC Infect Dis; 2010 Jun; 10():182. PubMed ID: 20569436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA).
    Wisniewski T; Klimko N; Laverdiere M; Kiertiburanakul S; Kliasova G; Trenschel R; Kumar RN
    Mycoses; 2011 Jul; 54(4):e148-53. PubMed ID: 20202110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
    León-Gil C; Ubeda-Iglesias A; Loza-Vázquez A; de la Torre MV; Raurich-Puigdevall JM; Alvarez-Sánchez B; Ortiz-Leyva C; Domínguez-Roldán JM; Socías-Crespi L; Garnacho-Montero J;
    Rev Esp Quimioter; 2012 Dec; 25(4):274-82. PubMed ID: 23303260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
    Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
    Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.
    Morrissey CO; Slavin MA; O'Reilly MA; Daffy JR; Seymour JF; Schwarer AP; Szer J
    Mycoses; 2007; 50 Suppl 1():24-37. PubMed ID: 17394607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
    Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
    BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
    Groetzner J; Kaczmarek I; Wittwer T; Strauch J; Meiser B; Wahlers T; Daebritz S; Reichart B
    J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections].
    Lichtenstern C; Pratschke J; Schulz U; Schmoeckel M; Knitsch W; Kaskel P; Krobot KJ; Weigand MA; Winkler M
    Anaesthesist; 2010 Dec; 59(12):1083-90. PubMed ID: 21069271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
    Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
    Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
    Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
    J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
    DiNubile MJ; Hille D; Sable CA; Kartsonis NA
    J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.